Teva Pharmaceutical Industries Ltd. (TEVA)

21.23
NYSE : Health Technology
Prev Close 21.23
Day Low/High 0.00 / 0.00
52 Wk Low/High 10.85 / 25.96
Avg Volume 11.75M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 22.11B
EPS -16.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Teva Presents 25-year Safety Data From Longest Continuous Trial Of COPAXONE® (glatiramer Acetate Injection) For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Teva Presents 25-year Safety Data From Longest Continuous Trial Of COPAXONE® (glatiramer Acetate Injection) For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced safety and tolerability results representing 25 years of data from the open-label extension study of the original U.

Teva To Present New Data At 34th European Committee For Treatment And Research In Multiple Sclerosis Congress In Berlin

Teva To Present New Data At 34th European Committee For Treatment And Research In Multiple Sclerosis Congress In Berlin

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on COPAXONE ® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (RMS), will be presented at the 34 th Congress of the European...

Teva To Report Third Quarter 2018 Financial Results On November 1, 2018

Teva To Report Third Quarter 2018 Financial Results On November 1, 2018

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 at 7:00 a.

Teva Announces Exclusive First-to-File Launch Of A Generic Version Of Cialis® In The United States

Teva Announces Exclusive First-to-File Launch Of A Generic Version Of Cialis® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis ®1 (tadalafil) tablets (2.

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'

Teva Announces Early Results Of Debt Tender Offer And Election Of Early Settlement

Teva Announces Early Results Of Debt Tender Offer And Election Of Early Settlement

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the early tender results in connection with its previously announced tender offers (the " Offers ") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and...

Stocks End Near Day's Lows on Expectations of New China Tariffs

Stocks End Near Day's Lows on Expectations of New China Tariffs

Stocks ended near their lows of the day as President Trump teased a trade announcement after the bell.

We Remain Bullish on Amgen Despite FDA's Approval of Competing Drug From Teva

Amgen's migraine prevention drug Aimovig is understood to be superior to Teva's Ajovy.

Teva Shares Pop as FDA Approves Its Migraine Drug

Teva Shares Pop as FDA Approves Its Migraine Drug

Ajovy is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the FDA to prevent migraines.

Teva To Present At The Morgan Stanley Global Healthcare Conference

Teva To Present At The Morgan Stanley Global Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Morgan Stanley Global Healthcare Conference in New York, NY.

Teva Canada Announces The Launch Of A Generic Version Of (PR)Abilify®, (PR)Teva-Aripiprazole Tablets For The Treatment Of Schizophrenia

Teva Canada Announces The Launch Of A Generic Version Of (PR)Abilify®, (PR)Teva-Aripiprazole Tablets For The Treatment Of Schizophrenia

- Currently Available in Canada - TORONTO, Sept. 10, 2018 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd.

Teva, NACHC And Direct Relief Provide Important Insights On Prescription Medicine Access For Underserved Patients At The AAM Conference

Teva, NACHC And Direct Relief Provide Important Insights On Prescription Medicine Access For Underserved Patients At The AAM Conference

BALTIMORE, Sept. 6, 2018 /PRNewswire/ -- Today at GRx + Biosims: Engineering the Future of Generic + Biosimilar Medicines, the Association for Accessible Medicines' (AAM) annual industry conference, a panel that examined prescription medicine access for...

Teva Announces $400 Million Debt Tender Offer

Teva Announces $400 Million Debt Tender Offer

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has commenced tender offers (the " Offers") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $400 million (the "...

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

Here's What Could Make the Market Turn Sour

First of all, watch the stocks making new lows.

Teva Notches Win With FDA Approval of Generic EpiPen

Teva Notches Win With FDA Approval of Generic EpiPen

The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.

Teva And Regeneron Announce Positive Topline Phase 3 Fasinumab Results In Patients With Chronic Pain From Osteoarthritis Of The Knee Or Hip

Teva And Regeneron Announce Positive Topline Phase 3 Fasinumab Results In Patients With Chronic Pain From Osteoarthritis Of The Knee Or Hip

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc.

Buffett Ups Stake in Teva

Buffett Ups Stake in Teva

Warren Buffett's Berkshire Hathaway increases its stake in the drugmaker to 43.2 million shares from 40.5 million shares at the end of March.

Teva Announces Updated Indication And Vial Presentation For GRANIX® (tbo-filgrastim) Injection In United States

Teva Announces Updated Indication And Vial Presentation For GRANIX® (tbo-filgrastim) Injection In United States

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.

3 Great Stocks to Buy If You Love Your Pet

3 Great Stocks to Buy If You Love Your Pet

The animal health market continues to be strong, and so is the outlook. Here are several plays on the space and why you should make them.

Teva Reports Second Quarter 2018 Financial Results

Teva Reports Second Quarter 2018 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2018.

Tesla Earnings, Trade Tariffs, Starbucks and Sonos - 5 Things You Must Know

Tesla Earnings, Trade Tariffs, Starbucks and Sonos - 5 Things You Must Know

U.S. stock futures trade lower on Thursday,, sparked by a tougher stance on China tariffs from the White House; Tesla jumps as revenue tops forecasts; Starbucks partners with Alibaba for a delivery business in China.

Teva Highlights Key Milestones Achieved In The 2017 Social Impact Report

Teva Highlights Key Milestones Achieved In The 2017 Social Impact Report

Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company's initiatives: building healthy communities and leading a responsible...

Teva To Report Second Quarter 2018 Financial Results On August 2, 2018

Teva To Report Second Quarter 2018 Financial Results On August 2, 2018

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.

Teva Announces Launch Of A Generic Version Of Uceris® In The United States

Teva Announces Launch Of A Generic Version Of Uceris® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris ®1 (budesonide) extended-release tablets, 9 mg, in the U.

Teva To Present New Fremanezumab Data, Including Long-Term Data, At The American Headache Society's 60th Annual Scientific Meeting

Teva To Present New Fremanezumab Data, Including Long-Term Data, At The American Headache Society's 60th Annual Scientific Meeting

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 23 abstracts, one late-breaking poster and three oral presentations of fremanezumab for the preventive treatment of migraine which will be presented at the American Headache...

TheStreet Quant Rating: D+ (Sell)